pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·26m ago·1 min read
save

Regeneron and Sanofi explore expanded partnership for Dupixent follow-on candidates

Jul 30, 2026·read at Endpoints ↗DealPositive

Regeneron and Sanofi said they are in early discussions about expanding their collaboration beyond the existing Dupixent partnership.

The companies indicated the potential scope could include development of follow-on products that build on Dupixent's platform, though details remain limited.

Both CEOs emphasized that the partnership has been one of the most productive in recent years, and they will continue to explore opportunities as they arise.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons”

read at Endpoints ↗
90 words · retrieved 7m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 37m agoReplimune defends melanoma drug decisions to FDA advisory panelEndpoints
  • 2h agoFirst round of Trump's 100% pharma tariffs won't start Friday as plannedEndpoints
  • 3h agoTrump's CDC pick Erica Schwartz clears crucial vote in SenateEndpoints
  • 4h agoUCB stock slides despite Bimzelx revenue beating forecastsEndpoints
  • 4h agoGarijo's plan to revamp Sanofi: an R&D cleanup, more M&A and a China pushEndpoints